A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphomae

Leukemia

Volumn 13, Issue 9, 1999, Pages 1434-1440

  Niitsu, N ^a   Sasaki, K ^a   Umeda, M ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

COP BLAM therapy; Non Hodgkin's lymphoma; Prognostic factor; Soluble Fas

Indexed keywords

FAS ANTIGEN;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; T CELL LYMPHOMA;

EID: 0032863482     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401502     Document Type: Article

References (30)

1. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the sFas antigen. J Biol Chem 1992; 267: 10709-10715.
2. Leithauser F, Dhein J, Mechtersheimer C, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-429.
3. Debatin K-M, Goldman CK, Waldman TA, Krammer PH. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 1993; 81: 2972-2977.
4. Trauth BC, Klas C, Peter AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
5. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
6. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B-and T-cell lines and increased serum levels in B-and T-cell leukemias. Blood 1995; 85: 1562-1569.
7. Shipp HA et al. A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993; 329: 987-994.
8. Hiddemann W, Coiffer B, Fisher RI, Cabanillas F, Cavali F, Nadler LM, De Vita VT, Lister TA, Armitage JO. Lymphoma classification: the gap between biology and clinical management is closing. Blood 1996; 88: 4085-4089.
9. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
10. Niitsu N, Umeda M. COP-BLAM regimen combined with granulocyte colony-stimulating factor (G-CSF) and high-grade non-Hodgkin's lymphoma. Eur J Haematol 1995; 55: 88-92.
11. Niitsu N, Umeda M. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate-and high-grade non-Hodgkin's lymphoma. Eur J Haematol 1996; 56: 163-167.
12. Pui C-H, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, Murphy SB. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987; 70: 624-628.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945; 1: 80-83.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
16. Cox DR. Regression models and life tables. J Stat Soc Brit 1972; 34: 187-202.
17. Munker R, Midis G, Owen-Schanb L, Andreff M. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 1996; 10: 1531-1533.
18. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, Akagi T. Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphoma. Am J Pathol 1994; 145: 330-337.
19. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin N Am 1995; 9: 451-473.
20. Kamihira S, Yamada Y, Hiragata Y, Yamaguchi J, Izumikawa K, Sugahara K, Tsuruta K, Atogami S, Tsukasaki K, Maeda T, Tomonaga M. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases. Intern Med 1997; 36: 166-170.
21. Yufu Y, Choi I, Itirase N, Tokor A, Noguchi Y, Goto T, Uike N, Kozuru M. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-cell lymphoma. Am J Hematol 1998; 58: 334-336.
22. Seishima M, Takemura M, Saito K, Sano H, Minatoguchi S, Fujiwara H, Hachiya T, Noma A. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Clin Chem 1996; 42: 1911-1914.
23. Preti HA, Cabanilas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127: 186-194.
24. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26: 251-259.
25. Christiansen I, Gidlof C, Kalkner KM, Hagberg H, Bennmarker H, Totterman T. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. Br J Haematol 1996; 92: 639-646.
26. Ristamaki R, Joensuu H, Lappalainen K, Teerenhovi L, Jalkanen S. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 4039-4045.
27. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 1997; 337: 529-534.
28. Munker R, Younes A, Cabanullas F, Andreeff M. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk Lymphoma 1997; 27: 517-521.
29. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 1997; 336: 1290-1297.
30. Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Parker P, Stein A, Smith E, Planas I, Kashyap A, Somlo G, Spielberger R, Fung E, Wong KK, Margolin K, Chow W, Sniccinski I, Vora N, Blume KG, Niland J, Forman SJ. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma: International index high and high-intermediate risk group. Blood 1997; 90: 3844-3852.